Outcomes of SWI/SNF complex‐deficient sinonasal carcinomas in a Southeast Asian cohort

Author:

Xu Xinni1ORCID,Wu Bingcheng2,Loh Kwok Seng13,Lim Wei Sian1,Tan Charmaine Si Min1,Low Terese Huiying4,Ong Yew Kwang1,Tan Jeng Swan3,Eu Donovan Kum Chuen1

Affiliation:

1. Department of Otolaryngology – Head & Neck Surgery National University Hospital Singapore Singapore

2. Department of Pathology National University Hospital Singapore Singapore

3. Department of Otolaryngology Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore

4. Department of Otolaryngology – Head & Neck Surgery Ng Teng Fong General Hospital Singapore Singapore

Abstract

AbstractBackgroundSWI/SNF complex‐deficient sinonasal carcinomas are rare, genetically distinct, and aggressive entities.MethodsSMARCB1 and SMARCA4 immunohistochemistry was retrospectively performed on a cohort of undifferentiated, poorly differentiated, and poorly defined sinonasal carcinomas. Survival outcomes were compared between SMARCB1/SMARCA4 (SWI/SNF complex)‐deficient and ‐retained groups.ResultsEight SWI/SNF complex‐deficient (six SMARCB1‐deficient, two SMARCA4‐deficient) cases were identified among 47 patients over 12 years. Triple‐modality treatment was more frequently utilized in SWI/SNF complex‐deficient carcinomas than in SWI/SNF complex‐retained carcinomas (71.4% vs. 11.8%, p = 0.001). After a median follow‐up of 21.3 (IQR 9.9–56.0) months, SWI/SNF complex‐deficient sinonasal carcinomas showed comparable recurrence rates (57.1% vs. 52.9%, p = 0.839), time‐to‐recurrence (7.3 [IQR 6.6–8.3] vs. 9.1 [IQR 3.9–17.4] months, p = 0.531), and overall survival (17.7 [IQR 11.8–67.0] vs. 21.6 [IQR 8.9–56.0] months, p = 0.835) compared to SWI/SNF complex‐retained sinonasal carcinomas.ConclusionTriple‐modality treatment may improve survival in SWI/SNF complex‐deficient sinonasal carcinomas.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3